A Study of LY3023414 in Japanese Participants With Advanced Cancer

Neoplasm Clinical Trial

Official title:

A Phase 1 Study of LY3023414 in Japanese Patients With Advanced Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02536586
• Other study ID #: 15838
• Secondary ID: I6A-JE-CBBH
• Status: Completed
• Phase: Phase 1
• Start date: September 2015
• Est. completion date: February 9, 2017

Study information

• Verified date: July 2018
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the tolerability of an investigational drug known as LY3023414 in Japanese participants with advanced cancer or cancer that has spread to another part(s) of the body. The study will also explore the safety of the drug. It will measure how much of the drug gets into the blood steam and how long the body takes to get rid of it. It will investigate anti-cancer activity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: February 9, 2017
• Est. primary completion date: February 9, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria

• Have histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic and must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed or for whom standard therapy would not be appropriate.

• Have the presence of measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

• Have adequate organ and coagulation function.

• Have discontinued all previous cancer therapies, and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 half-lives prior to study treatment, whichever is shorter, and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for at least 42 days.

• Are able to swallow capsules.

• Males must agree to use medically approved barrier contraceptive precautions during the study and for 3 months following the last dose of study drug.

• Females with childbearing potential: Must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug, must have had a negative serum or urine pregnancy test =7 days before the first dose of study drug.

• A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding enters the study, breastfeeding must cease from the day of the first study drug administration until at least 3 months after the last administration.

Exclusion Criteria

• Have serious pre-existing medical conditions.

• Have symptomatic central nervous system malignancy or metastasis.

• Have known acute or chronic leukemia or current hematologic malignancies that, in the judgment of the investigator and sponsor, may affect the interpretation of results.

• Have a known active fungal, bacterial, and/or known viral infection.

• Intolerance to any previous treatment with any phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitor. Treatment with any PI3K/AKT/mTOR inhibitor must have discontinued for at least 21 days or 5 half-lives prior to first study drug administration, whichever is shorter, and participants must have recovered from the acute effects of therapy.

• Have a second primary malignancy that, in the judgment of the investigator, and sponsor may affect the interpretation of results.

• Participants with active alcohol abuse, as determined by the investigator.

• Have a history of heart failure according to New York Heart Association Class =3.

• Have corrected QT (QTc) interval of >470 milliseconds (msec) on screening electrocardiogram (ECG).

• Have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus.

• Have any evidence of clinically active interstitial lung disease (ILD).

Related Conditions & MeSH terms

• Neoplasm

Intervention

Drug:
• LY3023414
LY3023414 administered orally.

Locations

Country	Name	City	State
Japan	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.	Chiba
Japan	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with LY3023414 Dose-Limiting Toxicities (DLT)		Cycle 1 (21 days)
Secondary	Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve (AUC) of LY3023414		Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.)
Secondary	Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3023414		Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.)
Secondary	Proportion of Participants With Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])		Baseline through study completion (estimated as up to five months)